How Long Does GLP-1 Take to Work?

Summary: Appetite changes appear within one to two weeks, blood sugar improves by week two to four, the scale moves at week four to eight, and trial endpoints land at month fifteen to seventeen.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: GLP-1 receptor agonists start working pharmacologically within hours of the first injection, you usually notice appetite and food noise changes within one to two weeks, blood sugar improves by week two to four, the scale begins to move around week four to eight, and the trial-published weight loss landmarks land at month six and again at month fifteen to seventeen. Faster than that is uncommon. Slower than that usually means the dose is still too low.

What follows is the week-by-week and month-by-month timeline, anchored to the actual phase-3 trial trajectories from STEP-1 (semaglutide, Wegovy) and SURMOUNT-1 (tirzepatide, Zepbound), with the variables that speed it up or slow it down.

Week 1: pharmacology kicks in, you barely feel it

Semaglutide reaches steady-state plasma concentration after four to five weeks of weekly injections ^[3]. Tirzepatide is similar ^[4]. That sounds like a long ramp, but the drug starts binding GLP-1 receptors in the gut, pancreas, and brain within hours of the first injection. The reason you do not feel a dramatic effect at week 1 is two things. First, the starting dose is intentionally low for tolerance, not for results. Wegovy starts at 0.25 mg weekly. Zepbound starts at 2.5 mg weekly. These are subtherapeutic on purpose. Second, the receptor-mediated changes take a few days to translate into the conscious experience of being less hungry.

What you might notice in week 1:

• A vague sense that meals you used to finish are now too much
• The constant background loop of food thoughts is quieter
• Mild nausea, especially after the injection day and the day after
• Occasional reflux or fullness that lingers longer than usual after eating

What you almost certainly will not notice in week 1:

• Anything on the scale. Day-to-day weight is dominated by water, glycogen, and food in transit. A 0.25 mg dose of semaglutide does not produce a meaningful caloric deficit in seven days.

Weeks 2 to 4: food noise drops, satiety arrives

By the end of week 2, most people on a starting GLP-1 dose can describe the change in their own words. The phrase "food noise" entered the public vocabulary precisely because it captures something pharmacologically real. GLP-1 receptors in the hypothalamus and brainstem modulate the homeostatic and hedonic drive to eat. When those receptors are stimulated steadily for two weeks, the volume on that drive goes down.

By week 4 you are usually still at the starting dose (Wegovy 0.25 mg, Zepbound 2.5 mg) and about to step up. Most people report:

• Portions naturally shrink by 20 to 40 percent without conscious effort
• Sweet cravings and alcohol cravings drop notably
• Restaurant meals feel intolerable in their full plated form
• Early satiety, that point where you simply cannot take one more bite, arrives sooner

Blood sugar improvement shows up in this window for people with type 2 diabetes or prediabetes. Fasting glucose drops first, postprandial spikes flatten next, and HbA1c (which is a 90-day average) starts to fall by month two or three. The cardiovascular outcomes trial SUSTAIN-6 reported HbA1c reductions becoming statistically significant within three months of starting semaglutide ^[5].

Weeks 4 to 8: the scale starts to move

This is the window where most people see a number they actually believe. In STEP-1, the semaglutide arm hit roughly 6 percent placebo-subtracted weight loss by week 20, with the curve already clearly separating from placebo by week 8 ^[1]. In SURMOUNT-1, the tirzepatide curve separated from placebo even earlier and steeper ^[2].

Concrete numbers from the STEP-1 weekly trajectory for semaglutide 2.4 mg ^[1]:

A person weighing 220 pounds at baseline is on average 13 pounds lighter by week 12 and about 33 pounds lighter at the 68-week trial endpoint. Tirzepatide at the 15 mg dose pushed that endpoint number to roughly 20.9 percent total body weight loss at 72 weeks in SURMOUNT-1 ^[2].

These are mean numbers. Real-world distributions are wide. STEP-1 reported that 86 percent of semaglutide patients lost at least 5 percent of body weight at 68 weeks, 69 percent lost at least 10 percent, 51 percent lost at least 15 percent, and 32 percent lost at least 20 percent ^[1]. The same trial showed that 7 percent of semaglutide patients lost less than 5 percent of body weight despite 68 weeks of treatment. Some people respond hard. Some respond modestly. The biology is not uniform.

Months 2 to 6: dose escalation cycles and the first plateau

Both semaglutide and tirzepatide have a forced titration schedule built into the FDA label ^[3][4]. The schedule exists because GI tolerance, not efficacy, is the rate-limiting factor for most people.

Wegovy titration schedule ^[3]:

Zepbound titration schedule ^[4]:

Every dose escalation behaves like a mini restart. Appetite suppression intensifies for the first week or two on the new dose, the scale picks up speed for a few weeks, and then the rate of loss settles into a slower curve until the next step-up. A plateau between dose steps is normal. A plateau at the maintenance dose is also normal, just later. The STEP-1 weight curve is steepest from week 8 to week 28, then flattens noticeably between week 40 and week 68 ^[1]. That flattening is biology, not failure.

Month 6: the first major landmark

At week 28 (roughly six months) semaglutide patients in STEP-1 had lost an average of 12.4 percent of starting body weight ^[1]. Tirzepatide at week 24 in SURMOUNT-1 had already passed 15 percent at the 15 mg dose ^[2]. Six months is when most patients have either:

• Reached the maintenance dose and are seeing the deepest part of the loss curve, or
• Plateaued early because they stopped titrating, dropped the medication, or never made it past a tolerability ceiling

The 5 percent body weight threshold is the FDA's clinical benchmark for "responder" status. By six months, the vast majority of people who will ever respond to GLP-1 therapy have crossed it. People who have lost less than 3 percent at six months on a maintenance dose are unlikely to suddenly catch up at twelve months. That is the dataset talking, not pessimism.

Month 12 to 17: the trial endpoints

STEP-1 measured weight loss at week 68, which is just over 15 months ^[1]. SURMOUNT-1 measured at week 72, which is just under 17 months ^[2]. Those endpoints were chosen because the weight loss curves were still trending down at month 12 in both trials. The body's adaptive responses (slowed metabolic rate, increased hunger signaling around the drug's coverage) eventually catch up, and the curve flattens. STEP-1 plateaued around week 60. SURMOUNT-1 was still showing slight downward trend at week 72 in the 15 mg arm ^[2].

Headline endpoint numbers:

That is the ceiling of what the average patient should expect from monotherapy at the published maximum doses. People who lose more than that are above the trial mean. People who lose less may still be inside the normal distribution. The 1-year mark is where the conversation shifts from "is this working" to "what is the maintenance plan."

What slows the timeline

The four most common reasons a real patient progresses slower than the trial curve:

1. Insufficient titration. The single biggest one. People who stall at 0.5 mg or 1.0 mg of semaglutide because side effects scared them, or because their prescriber paused the titration too long, never reach the dose where the trial data was generated. The therapeutic dose for weight loss in STEP-1 was 2.4 mg, not 1.0 mg ^[1]. Stalling at half the dose halves your expected loss, roughly speaking.
2. Dietary self-sabotage. GLP-1 reduces appetite, but it does not prevent calorie intake. Liquid calories (juice, sweetened coffee, alcohol), ultra-processed snack foods that bypass satiety signaling, and sugary "treats" eaten while appetite is suppressed can keep total intake near maintenance. People who lose weight slowly on GLP-1 are almost always still in a small deficit, not a meaningful one.
3. Baseline metabolic conditions. Hypothyroidism, PCOS, insulin resistance, certain antipsychotic and antidepressant medications, chronic sleep deprivation, and untreated obstructive sleep apnea all slow the response. These do not block the medication, they reduce the slope of the curve.
4. Inconsistent dosing. Skipped weeks, late injections (more than 48 hours past the scheduled day), and dose reductions made unilaterally to stretch a prescription all blunt steady-state pharmacology. The 4 to 5 week half-life of semaglutide forgives the occasional late dose, but a pattern of missed weeks costs you real loss.

What speeds the timeline

The variables that genuinely accelerate, within the limits of biology:

1. Faster titration if tolerated. Some prescribers use accelerated titration in patients with very high BMI or strong drug tolerance, moving up every two to three weeks instead of four. This is off-label but documented in clinical practice. It compresses the time to therapeutic dose by a month or two.
2. Protein intake at 1.2 to 1.6 g per kg body weight. The biggest lever you control. GLP-1 induced weight loss is unfortunately not all fat. Without adequate protein, roughly 25 to 40 percent of the weight lost is lean tissue, depending on the study. Higher protein intake preserves lean mass and keeps resting metabolic rate higher, which sustains the rate of fat loss instead of total weight loss.
3. Resistance training, twice weekly minimum. Same logic as protein. Loaded movement signals the body to retain muscle while in a caloric deficit. Two 30-minute sessions per week is enough to make a measurable difference in body composition at the trial endpoints.
4. Sleep. Seven to nine hours of consolidated sleep per night. Sleep deprivation raises ghrelin, lowers leptin, increases cortisol, and worsens insulin sensitivity. It works against every mechanism GLP-1 is trying to activate. The patients in STEP-1 and SURMOUNT-1 were not getting four hours of sleep a night, and you should not be either.

What about month 12 onward: does weight loss slow down?

Yes, by design. The biology of energy balance is built around defending body weight. As you lose fat mass, your resting metabolic rate falls (both because there is less tissue to feed and because the body downregulates thermogenesis), and your appetite hormones outside of the GLP-1 axis push back. By month 9 to 12 most people are in the slow-tailing portion of the curve. STEP-1 showed the loss rate dropping to a fraction of its mid-trial pace between week 40 and week 68 ^[1].

This is not the medication failing. This is the medication holding the position you fought to reach. The maintenance dose is doing the job it was designed for: keeping appetite suppressed enough that you stay in a small deficit or at maintenance, instead of regaining. People who stop the medication at this point typically regain about two-thirds of the lost weight within a year, which is also from the STEP withdrawal extension data.

What this looks like by age

Age does not change the pharmacology meaningfully. SURMOUNT-1 enrolled adults up to age 75 and showed similar weight loss percentages across age strata ^[2]. The differences come from:

• Slower metabolic rate at baseline (older adults need slightly tighter dietary attention)
• Greater risk of sarcopenia, which makes the protein and resistance training rules non-negotiable
• More medications on board, which raises the friction of dose escalation

The 6-month and 12-month landmarks still apply. People over 60 should expect the same percentage of body weight loss as people in their 30s on the same dose, provided the protein and training pieces are in place.

When to call your prescriber about timeline

Call sooner than the next scheduled check-in if:

• You have been at the maintenance dose for at least 12 weeks and have lost less than 3 percent of body weight
• Your appetite has rebounded toward pre-medication levels at any dose
• Your scale has been flat for more than 8 weeks at a non-maintenance dose
• You are losing weight but feel weak, fatigued, or are losing visible muscle, which suggests inadequate protein or excessive deficit
• GI side effects are forcing you to skip doses, which collapses the steady-state and stalls progress

Common questions about how long GLP-1 takes to work

How long does it take for GLP-1 to kick in?

Pharmacologically within hours, noticeably within one to two weeks for appetite, by week four to eight for the scale, and by week twelve for HbA1c reduction.

How fast does GLP-1 work for weight loss specifically?

Mean weight loss is about 2 percent by week 4, 4 percent by week 8, 7 percent by week 12, and 12 percent by week 28 in STEP-1, with tirzepatide running faster and deeper.

How soon do you see results from GLP-1 medications on the scale?

Most people see a real, sustained drop on the scale between week 4 and week 8 of treatment, once the body has been in a daily caloric deficit for long enough to clear out water and glycogen noise.

What is the normal weight loss on GLP-1 per month?

Roughly 1 to 2 percent of starting body weight per month during the active loss phase (months 2 through 6), tapering to 0.5 to 1 percent per month between months 6 and 12.

Can weight loss start after the first month?

Yes, and for many people it does. The first month is usually appetite changes with minimal scale movement, then the deficit catches up to the scale around weeks 4 to 6.

Does weight loss slow down after 6 months on GLP-1?

Yes, and it is expected. The STEP-1 curve flattens substantially after week 40. The maintenance dose then holds the loss instead of producing new loss.

How long before you notice fat loss versus water weight?

The first week or two of any weight change is mostly water and glycogen. Real fat loss, measurable in body composition terms, becomes detectable around week 4 and dominates by week 8.

Why is my GLP-1 not working yet?

Most often the dose is still below therapeutic, the titration was paused, or liquid calories and ultra-processed foods are filling the appetite gap. Check the dose first, then the food log, before doubting the molecule.

Does the response differ between semaglutide and tirzepatide?

Yes. Tirzepatide produces faster and deeper weight loss at maximum doses in head-to-head and trial-mean comparisons (15 to 21 percent versus 12 to 15 percent), with a similar timeline shape.

How long does GLP-1 stay in your system if you stop?

Semaglutide has a half-life of about 5 to 7 days, so it clears over 4 to 5 weeks. Tirzepatide is similar. Appetite returns gradually over that window, not overnight.

What this article does not cover

This is the timeline. Adjacent topics on this site cover the side effects week by week, the specific dose conversions for compounded semaglutide and tirzepatide, what to do at each plateau, and what happens when you stop the medication after a year. Use the search to find them. The numbers on this page come from the published STEP-1 and SURMOUNT-1 trial data, which is the strongest evidence available for what to expect, on average, when a GLP-1 receptor agonist is dosed at label-recommended levels for the recommended duration.